Drug Profile
Drisapersen - BioMarin Nederland
Alternative Names: 2'-O-methyl-phosphorothioate oligonucleotide; 2402968; GSK-2402968; GSK2402968A; h51AON23; Kyndrisa; PRO-051Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Prosensa
- Developer BioMarin Nederland
- Class Antisense oligonucleotides
- Mechanism of Action Dystrophin stimulants; RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Duchenne muscular dystrophy
Most Recent Events
- 21 Jul 2016 BioMarin Pharmaceuticals completes the phase III Drisapersen confirmatory trial for Duchenne muscular dystrophy (In children, In adolescents) in Belgium (SC) (EudraCT2014-005296-81)
- 31 May 2016 Discontinued - Phase-III for Duchenne muscular dystrophy in Argentina (SC)
- 31 May 2016 Discontinued - Phase-III for Duchenne muscular dystrophy in Australia (SC)